( 37 Thoracic Cancer Studies; 11 Breast C...)Making Science Personal: Lilly Oncology to Unveil 76 Studies at,ASCO 2007,Health

INDIANAPOLIS, May 23, 2007 /PRNewswire-FirstCall/ -- Lilly Oncology will unveil 76 studies at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 1-5, 2007. The company will present important data on GEMZAR(R) (gemcitabine HCl for injection), ALIMTA(R) (pemetrexed for injection), and enzastaurin, an investigational, oral, targeted therapy. There will also be numerous studies that continue to use GEMZAR and ALIMTA as chemotherapeutic foundations in innovative combinations with new targeted therapies.

"This is an exciting time in cancer research as we are moving away from 'one-size fits all' treatment," said Richard Gaynor, M.D., Lilly vice president, cancer research and global oncology platform leader. "Lilly's commitment to finding the right drug, at the right dose, for the right patient at the right time will be demonstrated at ASCO this year."

    Key Lilly Abstracts for ASCO 2007:

    -- ALIMTA(R) (pemetrexed for injection)

        -- Phase III Study of ALIMTA in First-line NSCLC

            -- Abstract # 7517: June 2, 2007; 3:00 p.m.

            -- Pemetrexed + carboplatin vs. gemcitabine + carboplatin in the

                treatment of stage IIIB/IV NSCLC


        -- Large Meta-analysis of Diverse Patients with NSCLC

            -- Publication: 2007 ASCO Meeting Program

            -- Effect of race on the safety and efficacy of pemetrexed therapy

               in locally advanced and metastatic non-small cell lung cancer

               (NSCLC)


        -- Phase II Evaluation of ALIMTA Using Accelerated Vitamin

           Supplementation in Small Cell Lung Cancer

            -- Abstract # 7726: June 3, 2007: 8:00 a.m.

            -- The impact of shortened vitamin supplementation lead-in time

               before pemetrexed in patients with relapsed small cell lung

               cancer (SCLC)


'"/>




Page: 1 2 
Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab
Binds to the EGF Receptor and Potentiates Radiotherapy
3. Suven Life Sciences Presenting Pre-clinical data of their
NCE’s SUVN-502 and SUVN-507at International Brain Research
Organization (IBRO) 2007 World Congress of Neuroscience
4. Advanced Life Sciences Announces Supplemental Efficacy Data from
First Pivotal Phase 3 Pneumonia Clinical Trial
5. Advanced Life Sciences to Host Conference Call to Discuss Data From
Cethromycins First of Two Phase 3 Pneumonia Trials
6. Genetics Journal Thimerosal/Autism Study the Best Science Drug
Company Money Can Buy
7. Sangamo BioSciences Announces Presentation of Phase 1 ZFP
Therapeutic Data at American Diabetes Association Meeting
8. Answerthink and LORENZ Life Sciences Group Announce Strategic
Alliance for the SAP Life Science Industry
9. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug,
AN2690; Findings Published in Science
10. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release
Formulation of Bromocriptine Mesylate) Accepted for Poster
Presentation at American Diabetes Association 67th Scientific
Sessions
11. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07
Teleconference to Answer Questions About TA-65, Their Telomerase
Activator With Proven Age Management Benefits